PROMIS NEUROSCIENCES INC. (PMN) Free cash flow
- Free cash flow · 12 months (USD): Value (m); Formula and calculation Operating cash flow minus capital spending; distinct from the saved levered FCF quote figure. Period ending 2026-06-30..
- Price / free cash flow · 12 months: Value (m); Formula and calculation Market cap / trailing-year free cash flow; inverse of FCF yield before percent scaling. Period ending 2026-06-30..
- Free cash flow yield · 12 months: Value (m); Formula and calculation (Operating cash flow − capital spending) / current market cap. Period ending 2026-06-30..
- Free cash flow margin · 12 months: Value (m); Formula and calculation (Operating cash flow − capital spending) / revenue. Period ending 2026-06-30..
Free cash flow
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Free cash flow · 12 months (USD) | (m) | Operating cash flow minus capital spending; distinct from the saved levered FCF quote figure. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
| Price / free cash flow · 12 months | (m) | Market cap / trailing-year free cash flow; inverse of FCF yield before percent scaling. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
| Free cash flow yield · 12 months | (m) | (Operating cash flow − capital spending) / current market cap. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
| Free cash flow margin · 12 months | (m) | (Operating cash flow − capital spending) / revenue. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
| Free cash flow per share · 12 months | (m) | (Trailing-year operating cash flow − capital spending) / reported quarter-end common shares. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
| Operating cash flow · 12 months | $-42.11M | Cash generated by operating activities. Period ending 2026-06-30. |
| Operating cash flow / net income · 12 months | 1.00× | Operating cash flow / net income. Period ending 2026-06-30. $-42.11M ÷ $-42.23M ≈ 1.00× |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Operating cash flow | -42.11M USD | Net Cash Provided by (Used in) Operating Activities |
| Capital spending | (m) | Payments to Acquire Property, Plant, and Equipment |
| Market cap | (m) | |
| Free cash flow | (m) | Net Cash Provided by (Used in) Operating Activities · Payments to Acquire Property, Plant, and Equipment |
| Revenue | (m) | |
| Quarter-end shares | (m) | Common Stock, Shares, Outstanding |
| Net income | -42.23M USD | Net Income (Loss) Attributable to Parent |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Free cash flow | FCF per share | Operating cash flow | Capital spending (USD) | Market cap (USD) | Revenue (USD) | Quarter-end shares (shares) | Net income (USD) | Price / FCF | FCF yield | FCF margin | Cash conversion |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | (m) | (m) | $-42.11M | (m) | (m) | (m) | (m) | $-42.23M | (m) | (m) | (m) | 1.00× |
| 2026-03-31 | (m) | (m) | $-35.58M | (m) | (m) | (m) | (m) | $-40.62M | (m) | (m) | (m) | 0.88× |
| 2025-12-31 | (m) | (m) | $-28.12M | (m) | (m) | (m) | (m) | $-39.72M | (m) | (m) | (m) | 0.71× |
| 2025-09-30 | (m) | (m) | $-27.55M | (m) | (m) | (m) | (m) | $-29.28M | (m) | (m) | (m) | 0.94× |
| 2025-06-30 | (m) | (m) | $-24.17M | (m) | (m) | (m) | (m) | $-8.43M | (m) | (m) | (m) | 2.87× |
| 2025-03-31 | (m) | (m) | $-21.82M | (m) | (m) | (m) | (m) | $-933.94K | (m) | (m) | (m) | 23.36× |
| 2024-12-31 | (m) | (m) | $-27.18M | (m) | (m) | (m) | (m) | $2.78M | (m) | (m) | (m) | -9.78× |
| 2024-09-30 | (m) | (m) | $-22.23M | (m) | (m) | (m) | (m) | $-563.35K | (m) | (m) | (m) | 39.45× |
| 2024-06-30 | (m) | (m) | $-17.93M | (m) | (m) | (m) | (m) | $-12.20M | (m) | (m) | (m) | 1.47× |
| 2024-03-31 | (m) | (m) | $-18.57M | (m) | (m) | (m) | (m) | $-11.89M | (m) | (m) | (m) | 1.56× |
| 2023-12-31 | (m) | (m) | $-10.84M | (m) | (m) | (m) | (m) | $-13.21M | (m) | (m) | (m) | 0.82× |
| 2023-09-30 | (m) | (m) | $-11.64M | (m) | (m) | (m) | (m) | $-16.90M | (m) | (m) | (m) | 0.69× |
| 2023-06-30 | (m) | (m) | $-13.90M | (m) | (m) | (m) | (m) | $-20.49M | (m) | (m) | (m) | 0.68× |
| 2023-03-31 | (m) | (m) | $-16.23M | (m) | (m) | (m) | (m) | $-20.93M | (m) | (m) | (m) | 0.78× |
| 2022-12-31 | $-17.04M | (m) | $-17.03M | $1.98K | (m) | (m) | (m) | $-18.06M | (m) | (m) | (m) | 0.94× |
| 2022-09-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2022-06-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2022-03-31 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2021-12-31 | $-9.31M | (m) | $-9.31M | $6.04K | (m) | (m) | (m) | $-9.79M | (m) | (m) | (m) | 0.95× |
| 2021-09-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2021-06-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Milestone Pharmaceuticals Inc. (MIST) | $0.098B | -2.00 | |
| Polaryx Therapeutics, Inc. (PLYX) | United States | $0.106B | |
| Biomea Fusion, Inc. (BMEA) | United States | $0.107B | -3.30 |
| CITIUS ONCOLOGY, INC. (CTOR) | United States | $0.097B | -1.49 |
| Anixa Biosciences Inc (ANIX) | United States | $0.096B | |
| Equillium, Inc. (EQ) | United States | $0.109B | -11.27 |
| GENELUX Corp (GNLX) | United States | $0.110B | -3.83 |
| BICYCLE THERAPEUTICS PLC (BCYC) | $0.112B | -1.56 | |
| Quantum Cyber N.V. (QUCY) | $0.113B | ||
| Immuneering Corp (IMRX) | United States | $0.113B | -12.51 |